成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage
  2. Endogenous Metabolite PPAR
  3. Oleoylethanolamide

Oleoylethanolamide  (Synonyms: N-Oleoylethanolamide; Oleamide MEA; Oleic acid monoethanolamide)

目錄號: HY-107542 純度: 99.94%
COA 產品使用指南

Oleoylethanolamide 是一種高親和力的內源性 PPAR-α 激動劑,可用于肥胖和動脈硬化的相關研究。

MCE 的所有產品僅用作科學研究或藥證申報,我們不為任何個人用途提供產品和服務

Oleoylethanolamide Chemical Structure

Oleoylethanolamide Chemical Structure

CAS No. : 111-58-0

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(單位)同一產品試用裝僅限申領一次,同一機構(單位)一年內

     可免費申領三個不同產品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥880
In-stock
1 mg ¥363
In-stock
5 mg ¥800
In-stock
10 mg ¥1200
In-stock
50 mg ¥4200
In-stock
100 mg 現(xiàn)貨 詢價
200 mg   詢價  
500 mg   詢價  

* Please select Quantity before adding items.

Customer Review

Other Forms of Oleoylethanolamide:

MCE 顧客使用本產品發(fā)表的 1 篇科研文獻

查看 PPAR 亞型特異性產品:

  • 生物活性

  • 實驗參考方法

  • 純度 & 產品資料

  • 參考文獻

生物活性

Oleoylethanolamide is a high affinity endogenous PPAR-α agonist, which plays an important role in the treatment of obesity and arteriosclerosis.

IC50 & Target[1]

Human Endogenous Metabolite

 

PPAR-α

 

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
786-0 GI50
35.4 μg/mL
Compound: 4c
Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human 786-0 cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
HEK293 EC50
2.2 μM
Compound: OEA
Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay
Agonist activity at human GPR119 expressed in HEK293 cells assessed as stimulation of cAMP level measured after 60 mins by HTRF assay
[PMID: 27825553]
HEK293 EC50
2.2 μM
Compound: OEA
Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay
Agonist activity at human GPR119 expressed in HEK293 cells assessed as increase in cAMP stimulation measured after 60 mins by TR-FRET assay
[PMID: 28408218]
HEK293 EC50
2.2 μM
Compound: OEA
Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins
Agonist activity at human GPR119 expressed in HEK293 cells assessed as cAMP accumulation after 60 mins
[PMID: 23357035]
HEK293 EC50
2200 nM
Compound: OEA
Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine
Agonist activity at human GPR119 transfected in HEK293 cells assessed as concentration for 50 % cAMP stimulation of oleylethanolamine
[PMID: 23374864]
HeLa EC50
0.12 μM
Compound: OEA
Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay
Transactivation of human Gal4 fused PPARalpha LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay
[PMID: 27622746]
HeLa EC50
1.1 μM
Compound: OEA
Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay
Transactivation of human Gal4 fused PPARdelta LBD transfected in human HeLa cells after 7 hrs by dual-luciferase reporter gene assay
[PMID: 27622746]
MCF7 EC50
152 nM
Compound: OEA
Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay
Agonist activity at human PPARalpha transfected in human MCF7 cells after 16 hrs by luciferase reporter gene assay
[PMID: 26226490]
MCF7 EC50
152 nM
Compound: OEA
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 16 hrs by luciferase reporter gene assay
[PMID: 24936232]
MCF7 EC50
185 nM
Compound: OEA
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay
Agonist activity at human PPARalpha expressed in MCF7 cells co-transfected CPTI DR1-type RE after 6 hrs by luciferase reporter gene assay
[PMID: 24936232]
MCF7 GI50
25.9 μg/mL
Compound: 4c
Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MCF7 cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
NCI/ADR-RES GI50
9.1 μg/mL
Compound: 4c
Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI/ADR-RES cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
NCI-H460 GI50
36.5 μg/mL
Compound: 4c
Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human NCI-H460 cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
OVCAR-3 GI50
35.4 μg/mL
Compound: 4c
Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human OVCAR3 cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
PC-3 GI50
16.9 μg/mL
Compound: 4c
Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
RBL-2H3 IC50
> 50 μM
Compound: 10
Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2
Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 2
[PMID: 31618024]
SK-OV-3 IC50
24 μM
Compound: N-oleylethanolamine
Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC
Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by HPLC
[PMID: 20085856]
SK-OV-3 IC50
28 μM
Compound: N-oleylethanolamine
Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay
Inhibition of ceramidase in human SKOV3 cells assessed as hydrolysis of N-((2S,3R)-1,3-dihydroxy-5-((2-oxo-2H-chromen-7- yl)oxy)pentan-2-yl)palmitamide at 16 uM after 24 hrs at 37 degC by umbelliferone formation based fluorescence intensity assay
[PMID: 20085856]
U-251 GI50
27.3 μg/mL
Compound: 4c
Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human U251 cells after 48 hrs by sulforhodamine B assay
[PMID: 25510639]
體外研究
(In Vitro)

油酰乙醇胺 (OEA) 是一種內源性 PPAR-α 配體,可減輕靶向肝星狀細胞的肝纖維化。Oleoylethanolamide 通過 PPAR-α 在體外抑制 TGF-β1 誘導的肝星狀細胞 (HSC) 活化。為了評估油酰乙醇胺對 HSC 活化的影響,通過 qPCR 檢查了 TGF-β1 刺激的 HSC 中 α-SMA 和 Col1a 的表達水平。在用 TGF-β1 (5 ng/mL) 刺激 48 小時的 CFSC 細胞組中,α-SMA 和 Col1a 的 mRNA 水平被顯著誘導,而當用油酰乙醇胺處理時,mRNA 水平以劑量依賴性方式被抑制。免疫熒光和蛋白質印跡結果表明,油酰乙醇胺抑制劑量依賴性地抑制 α-SMA 的蛋白質表達,α-SMA 是 HSC 活化的標志物。Oleoylethanolamide 對 HSC 活化的抑制作用被 PPAR-α 拮抗劑 MK886 (10 μM) 完全阻斷。此外,PPAR-α 的 mRNA 和蛋白質表達水平在 TGF-β1 刺激下下調,而油酰乙醇胺處理以劑量依賴性方式恢復這些變化。此外,在 TGF-β1 刺激存在的情況下,Smad 2/3 的磷酸化被上調,這與觀察到的對 HSC 活化的影響一致,而油酰乙醇胺 (10 μM) 降低了用 TGF-β1 模擬的 CFSC 中 Smad2/3 的磷酸化[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內研究
(In Vivo)

油酰乙醇胺 (OEA) 可顯著抑制肝纖維化小鼠模型中促纖維化細胞因子 TGF-β1 負調節(jié) TGF-β1 信號通路 (α-SMA、膠原蛋白 1a 和膠原蛋白 3a) 中的基因。油酰乙醇胺 (5 mg/kg/天,腹膜內注射,腹膜內注射) 通過阻斷肝星狀細胞 (HSC) 的活化,顯著減緩兩種實驗動物模型的肝纖維化進程[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial
分子量

325.53

Formula

C20H39NO2

CAS 號
性狀

固體

顏色

White to off-white

結構分類
初始來源
運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式
Powder -20°C 3 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細胞實驗: 

DMSO 中的溶解度 : 20.83 mg/mL (63.99 mM; 超聲助溶; 吸濕的 DMSO 對產品的溶解度有顯著影響,請使用新開封的 DMSO)

配制儲備液
濃度 溶劑體積 質量 1 mg 5 mg 10 mg
1 mM 3.0719 mL 15.3596 mL 30.7191 mL
5 mM 0.6144 mL 3.0719 mL 6.1438 mL
查看完整儲備液配制表

* 請根據(jù)產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。
儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲存時,請在6個月內使用,-20°C儲存時,請在1個月內使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗:

請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
——為保證實驗結果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當保存;體內實驗的工作液,建議您現(xiàn)用現(xiàn)配,當天使用;
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.08 mg/mL (6.39 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑: 10% DMSO    90% Corn Oil

    Solubility: ≥ 2.08 mg/mL (6.39 mM); 澄清溶液

    此方案可獲得 ≥ 2.08 mg/mL(飽和度未知)的澄清溶液,此方案實驗周期在半個月以上的動物實驗酌情使用。

    1 mL 工作液為例,取 100 μL 20.8 mg/mL 的澄清 DMSO 儲備液加到 900 μL玉米油中,混合均勻。

動物溶解方案計算器
請輸入動物實驗的基本信息:

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

由于實驗過程有損耗,建議您多配一只動物的量
請輸入您的動物體內配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購。 ,Tween 80,均可在 MCE 網(wǎng)站選購。
計算結果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲備液濃度超過該產品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術支持聯(lián)系。
動物實驗體內工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL  μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上,請謹慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產品資料

純度: 99.94%

參考文獻
Cell Assay
[1]

CFSC, HSC cell lines are first obtained from cirrhotic rat liver, and have a similar phenotype to that of early passage primary HSCs. CFSC cells are cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin. All cells are cultured in 6-well culture plates under 37°C and 5% CO2 in an incubator. The medium is replaced every two days, and the cells are harvested and diluted at a ratio of 1:3 twice a week. In experiments, HSCs are pretreated with the experimental concentration of Oleoylethanolamide (30 μM, 10 μM, 3 μM) before stimulation with 5 ng/mL TGF-β1. mRNA expression levels of α-SMA (A) and Col1a (B) are analyzed by real-time PCR[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[1]

Mice[1]
The Sv/129 mice and PPAR-α knockout mice are maintained in a room with controlled temperature (21-23°C), humidity (55-60%) and lighting (12 h light/dark cycles) and given water ad libitum. Mice are randomly divided for methionine choline-deficient (MCD) and thioacetamide (TAA) experiments. In the MCD-diet feeding experiment, wild-type Sv/129 mice and PPAR-α knockout mice are each divided into three groups (n=8 /group): (i) control group receive normal diet; (ii) fed with MCD diet and injected with the vehicle (5% Tween-80+5% PEG400+90% saline, 5 mL/kg/day, 8 weeks, intraperitoneal injection, i.p.); (iii) fed with MCD diet along with Oleoylethanolamide administration (5 mg/kg/day; 8 weeks, i.p.). In another set of experiment, all the wild-type mice and PPAR-α knockout mice are given standard chow diet, and are randomly separated into three groups: the control group is not administrated TAA or Oleoylethanolamide but is injected with the saline; the TAA group is injected with TAA (160 mg/kg, three times per week, 6 weeks, dissolved in saline, i.p.) plus the corresponding vehicle; the Oleoylethanolamide group is both injected with TAA and Oleoylethanolamide (5 mg/kg/day; 6 weeks, i.p.)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻

完整儲備液配制表

* 請根據(jù)產品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產品失效。
儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲存時,請在6個月內使用,-20°C儲存時,請在1個月內使用。

可選溶劑 濃度 溶劑體積 質量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.0719 mL 15.3596 mL 30.7191 mL 76.7978 mL
5 mM 0.6144 mL 3.0719 mL 6.1438 mL 15.3596 mL
10 mM 0.3072 mL 1.5360 mL 3.0719 mL 7.6798 mL
15 mM 0.2048 mL 1.0240 mL 2.0479 mL 5.1199 mL
20 mM 0.1536 mL 0.7680 mL 1.5360 mL 3.8399 mL
25 mM 0.1229 mL 0.6144 mL 1.2288 mL 3.0719 mL
30 mM 0.1024 mL 0.5120 mL 1.0240 mL 2.5599 mL
40 mM 0.0768 mL 0.3840 mL 0.7680 mL 1.9199 mL
50 mM 0.0614 mL 0.3072 mL 0.6144 mL 1.5360 mL
60 mM 0.0512 mL 0.2560 mL 0.5120 mL 1.2800 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產品:

Your information is safe with us. * Required Fields.

   產品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機構名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產品名稱:
Oleoylethanolamide
目錄號:
HY-107542
需求量: